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Introduction {#sec005}
============

Primary Sjogren's syndrome (pSS) is a chronic systemic autoimmune disease characterized mainly by symptoms of ocular and oral dryness. However, up to 20% of patients have disease-related extra-glandular manifestations \[[@pone.0226498.ref001]\]. Autoantibodies to the autoantigens Ro/SS-A and La/SS-B are the most specific biomarkers for pSS, whereas cryoglobulins and hypocomplementaemia are the major prognostic markers of disease activity \[[@pone.0226498.ref002]\]. These patients are also at increased risk of having associated malignancies, particularly non-Hodgkin's lymphoma \[relative risk (RR)\], (RR = 13.76) \[[@pone.0226498.ref003],[@pone.0226498.ref004]\].

Treatment of patients with pSS is usually symptomatic (artificial tears and saliva replacement). None of the conventional immunosuppressant therapies are of proven effectiveness for systemic features of the disease. Thus, there is a growing interest in using current biological therapies in the treatment of SS \[[@pone.0226498.ref005]--[@pone.0226498.ref007]\]. In order to define key inclusion and response criteria in clinical trials with biologics, it is important to have objective measures of both disease activity and disease damage. Recently, standardized outcome tools for measuring disease-specific activity and patients' reported symptoms have been developed by the European League Against Rheumatism (EULAR) SS study group: the EULAR SS Disease Activity Index (ESSDAI) for systemic features of pSS and the EULAR SS Patient-Reported Index (ESSPRI) for patient symptoms \[[@pone.0226498.ref008],[@pone.0226498.ref009]\]. The distinction between disease activity (reversible) and damage (irreversible) has always been a matter of debate. For this purpose, two clinical indexes were derived from Italian authors in 2007: Sjogren's Syndrome Disease Damage Index (SSDDI) for assessment of disease damage and Sjogren's Syndrome Disease Activity Index (SSDAI) for disease activity \[[@pone.0226498.ref010]\]. The alterations in salivary glands are important parameters included in both disease activity indexes. The glandular domain in the ESSDAI and the new appearance or increased swelling of major salivary glands in the SSDAI contribute a significant number of points to the total score of disease activity. Apart from the size, the morphological changes in the salivary glands in pSS (either related to disease activity or damage) may be the important components of the clinical indexes. Among the modern imaging techniques, salivary ultrasonography (sUS) has an established role in the diagnosis and follow-up of pSS patients \[[@pone.0226498.ref011]--[@pone.0226498.ref016]\]. Recently, studies have shown that sUS is able to reveal improved salivary gland echostructure in patients with SS receiving rituximab \[[@pone.0226498.ref017],[@pone.0226498.ref018]\]. These results indicate the reversibility of some of the salivary gland changes, most likely reflecting disease activity as opposed to disease-induced damage. Therefore, the presence of salivary gland fibrosis or atrophy detected by sUS could contribute to selecting the subset of pSS patients who are likely not to benefit from immunomodulatory treatment.

The purpose of our study was to assess the association between sUS findings and disease activity and damage in pSS patients. Here, we demonstrated the potential prognostic role of sUS as a tool in the assessment of disease activity.

Materials and methods {#sec006}
=====================

Participants {#sec007}
------------

The cross-sectional study enrolled 303 pSS patients who fulfilled the American-European Consensus Group (AECG) classification criteria \[[@pone.0226498.ref019]\]. For sUS evaluation, the control group included 111 healthy subjects without any symptoms of dryness and concomitant autoimmune or thyroid disease. The study was approved by the local Ethics Committee Institute of Rheumatology (number 20/1-51). All patients gave informed written consent.

The questionnaire-based evaluation included the following: ocular symptoms; oral symptoms; ocular signs (Rose Bengal test); salivary gland involvement (sialo-scintigraphy and/or biopsy of minor salivary glands (MSGs) evaluated by the Chisholm and Mason scale); serological tests, including rheumatoid factor (RF), antinuclear antibody (ANA), and antibodies to the extractable nuclear antigens SS-A and SS-B; symptoms/signs suggestive of disease-related extra-glandular manifestations; and related current treatments. The sUS examination was performed simultaneously with the other diagnostic procedures.

Assessment of SS disease activity and damage by clinical indexes {#sec008}
----------------------------------------------------------------

At enrolment, physicians completed the ESSDAI for each pSS patient. The ESSDAI (0--123) proposes the evaluation of 12 domains or organ systems (constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, peripheral nervous system, central nervous system, muscular, haematological and biology). Low activity (ESSDAI\<5), moderate activity (5≤ESSDAI≤13) and high activity (ESSDAI≥14) levels were defined \[[@pone.0226498.ref008]\]. Physicians completed the Sjogren's Syndrome Disease Activity Index (SSDAI) and the Sjogren's Syndrome Disease Damage Index (SSDDI) \[[@pone.0226498.ref010]\]. The SSDAI is a global score (0--21) including the following items (constitutional, change in salivary gland swelling, articular symptoms, haematologic features, pleuropulmonary symptoms, change in vasculitis, renal involvement and peripheral neuropathy). An SSDAI score ≥5 was defined as a high level of activity \[[@pone.0226498.ref010]\]. The SSDDI comprises a three-domain assessment (ocular, oral and systemic damage). The systemic domain was further classified into neurological, renal, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, endocrine and malignancy sub-domains. The maximum score for each item was 1, and it has 27 items in total \[[@pone.0226498.ref010]\].

All patients completed the ESSPRI, a VAS scale (0--10) for dryness, fatigue and pain \[[@pone.0226498.ref009]\].

Salivary gland ultrasonography {#sec009}
------------------------------

The parotid and submandibular glands were examined by US using a GE LogiqE9 with a linear high-frequency transducer (6--15 MHz). The parotid glands were evaluated in a longitudinal and cross-sectional plane and the submandibular glands in a longitudinal plane. All ultrasound scans were performed by the same examiner (VM), blinded to the clinical diagnosis. The de Vita scoring system \[[@pone.0226498.ref020]\] was used for graded changes in the parenchymal homogeneity of salivary glands: grade 0 (normal homogenous parenchyma); grade 1 (mild level of inhomogeneity, with isolated and small hypoechoic areas, without hyperechoic bands); grade 2 (moderate inhomogeneity with multiple hypoechoic areas and/or few hyperechoic bands); grade 3 (severe inhomogeneity with large and confluent hyperechoic areas and diffuse hyperechoic bands) ([Fig 1](#pone.0226498.g001){ref-type="fig"}). The sUS score (0--6) represents the sum of the single scores of each pair of parotid and submandibular glands. Disease activity by US was graded into three groups: normal (US score 0--1), moderate (US score 2--4) and severe (US score 5--6).

![Parenchymal inhomogeneity of the salivary glands demonstrated by ultrasonography.\
a) Normal salivary gland (grade 0); b) a mild level of salivary inhomogeneity with isolated hypoechoic areas (grade 1); c) evident level of salivary inhomogeneity (grade 2); and d) gross level of salivary inhomogeneity (grade 3).](pone.0226498.g001){#pone.0226498.g001}

Statistical analysis {#sec010}
====================

All statistical analyses were performed using Statistical Package for Social Science (SPSS) software version 21.0. For statistical comparison, Student's t test, chi-square test, and Fisher's exact test were used as appropriate. Spearmen\'s test was used for correlation analysis. A receiver operating characteristic (ROC) curve was used to determine the cut-off value of the pathological sUS score with the highest level of accuracy. We calculated the diagnostic accuracy of a de Vita score ≥ 5 in comparison with ESSDAI, ESSPRI, SSDDI and SSDAI. All possible variables were first analysed through univariate logistic regression, and only significant variables were then summarized in a multivariate logistic regression model. The de Vita score was analysed as a potential predictor with a normal score as the reference. For all statistical analyses, p values less than 0.05 were considered statistically significant.

Results {#sec011}
=======

Characteristics of patients with pSS {#sec012}
------------------------------------

A total of 303 pSS patients (96.7% females) were enrolled in the study. The control group consisted of 111 healthy controls (97.3% females). There was no statistically significant difference in the mean age between pSS patients and healthy controls (54 ±12 vs.52 ±15, p = 0.131). The general characteristics of pSS patients are presented in [Table 1](#pone.0226498.t001){ref-type="table"}. The frequencies of domains in different ESSDAI and ESSPRI scores are presented in [S1](#pone.0226498.s001){ref-type="supplementary-material"} and [S2](#pone.0226498.s002){ref-type="supplementary-material"} Tables.

10.1371/journal.pone.0226498.t001

###### General characteristics of pSS patients.
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  Characteristic                                                            pSS patients (N = 303)
  ------------------------------------------------------------------------- ------------------------
  Age (years), mean ±SD                                                     54.03±11.95
  Female sex, number (%)                                                    293 (96.7)
  Disease duration (years), med (min-max)                                   5 (1--22)
  \< 5 years, n (%)                                                         128 (43)
  5--10 years, n (%)                                                        113 (38)
  \>10 years, n (%)                                                         59 (20)
  Clinical signs                                                            
  Ocular symptoms, n (%)                                                    275 (91.4)
  Oral symptoms, n (%)                                                      278 (92.4)
  Lymphoma, n (%)                                                           8 (2.6)
  Diagnostic tests                                                          
  Positive keratoconjunctivitis sicca, n (%)                                197(96.1)
  Positive scialo-scintigraphy[ɸ](#t001fn002){ref-type="table-fn"}, n (%)   150/152 (98.7)
  Positive biopsy of MSG[ɸ](#t001fn002){ref-type="table-fn"}, n (%)         190/219 (86.8)
  Positive RF, n (%)                                                        212 (70)
  Positive ANA, n (%)                                                       223 (73.6)
  Positive Anti-SSA Ab, n (%)                                               254 (83.8)
  Positive Anti-SSB Ab, n (%)                                               153 (50.5)
  Disease activity indexes                                                  
  ESSDAI, med (min-max), IQR                                                6 (0--75) 8
  ESSDAI ≥5, n (%)                                                          201 (66.3)
  ESPPRI, med (min-max), IQR                                                6 (0--10) 2.67
  ESPPRI ≥5, n (%)                                                          219 (72.3)
  SSDAI, med (min-max), IQR                                                 5 (0--18), 3
  SSDAI ≥5, n (%)                                                           160 (53.2), 3
  SSDDI med (min-max), IQR                                                  2 (0--12)
  Current treatments                                                        
  Glucocorticoids, n (%)                                                    161 (53.1)
  Hydroxychloroquine (n%)                                                   225 (74.3)
  Azatioprine, n (%)                                                        17 (4.1)
  Methotrexate, n (%)                                                       18 (4.3)
  Cyclophosphamide, n(%)                                                    3 (1)

Except where indicated otherwise, values are the number n, (%); ESSDAI, EULAR Sjogren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjogren's Syndrome Patient Reported Index; EULAR European League Against Rheumatism; SSDAI, Sjogren's Syndrome Disease Activity Index (SSDAI); SSDDI, Sjogren's Syndrome Disease Damage Index; MSG: minor salivary glands; RF: rheumatoid factor; ANA: antinuclear antibody; Anti-SSA Ab, anti-SSA antibody; Anti-SSB Ab, anti-SSB antibody.

ɸ Values of objective tests given as rates of positive results (positive/total)

Ultrasonography findings and correlations {#sec013}
-----------------------------------------

In comparison to healthy controls, the calculated sUS AUC-ROC was 0.96 (0.009) (95% CI 0.94--0.97), which reached a range of very high accuracy. The optimal cut-off for sUS score was set at ≥ 2, with the best ratio of sensitivity (89.6%) and specificity (86.7%). Two hundred seventy-one (89.7%) patients with pSS and only 8 (8.6%) healthy controls had sUS scores ≥ 2. Out of 271 pSS patients with pathological sUS, 197 (65.2%) had moderate sUS activity, and 74 (24.5%) had severe sUS activity.

The overall sUS score correlated directly with the age of patients (r = 0.09, p = 0.05), biopsy of MSG (r = 0.17, p = 0.01), SSDDI (r = 0.16, p = 0.003), SSDAI (r = 0.22, p\<0.0001) and ESSDAI (r = 0.428, p\<0.0001). Furthermore, pathological sUS correlated with the constitutional domain (r = 0,16, p = 0.004), lymphadenopathy (r = 0.25, p\<0.001), glandular domain (r = 0,25, p\<0.001) and muscular domain (r = 0,16, p = 0.008) within the ESSDAI. Additionally, pathological sUS correlated with the glandular domain within the SSDDI (r = 0,16, p = 0.004). Disease duration and ESSPRI did not correlate with sUS score (p\>0.005).

Characteristics of pSS patients and ESSDAI and ESPRI disease activity {#sec014}
---------------------------------------------------------------------

[Table 2](#pone.0226498.t002){ref-type="table"} presents the characteristics of pSS patients with different grade ESSDAI and ESSPRI indexes. Patients with moderate and high ESSDAI scores exhibited significantly higher US activity (p = 0.006), were more frequently positive for anti-SSA (p = 0.014) and had more common lymphoma (p = 0.043) in comparison to those of SS patients with low ESSDAI scores. These patients were taking corticosteroids more frequently (p = 0.008), azathioprine (p = 0.003) and methotrexate (p = 0.038). Patients with moderate ESSPRI scores were older (p = 0.024) and more often had both xerophthalmia (p = 0.003) and xerostomia (p = 0.022) in comparison to those of pSS patients with low disease activity.

10.1371/journal.pone.0226498.t002

###### Characteristics of pSS patients and comparison according to the level of disease activity using the ESSDAI and ESSPRI.
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  ----------------------------------------------------------------------------------------------------------------------
  Characteristic                               ESSDAI        p value       ESSPRI   p value                     
  -------------------------------------------- ------------- ------------- -------- ------------- ------------- --------
  Age, mean±SD                                 55.19±12.02   53.68±11.89   0.299    51.48±13.10   55.20±11.33   0.024

  Female, n (%)                                100 (98.0)    194 (96.0)    0.356    80 (96.4)     214 (96.8)    0.846

  Duration of disease, med\                    5 (1--20)     5 (0--22)     0.456    5 (1--22)     5 (0--20)     0.828
  (min-max)                                                                                                     

  Xerophthalmia, n (%)                         94 (92.2)     183 (90.6)    0.651    69 (83.1)     208 (94.1)    0.003

  Xerostomia, n (%)                            94 (91.2)     186 (92.1)    0.906    72 (86.7)     208 (94.5)    0.022

  Positive keratoconjunctivitis sicca, n (%)   65 (95.6)     133 (96.4)    0.783    59 (96.7)     139 (95.9)    0.771

  Positive sialo-scintigraphy, n (%)           47 (97.9)     103 (99.0)    0.533f   39 (100.0)    111 (98.2)    0.651

  Positive biopsy of MSG, n (%)                55 (84.6)     136 (88.3)    0.381    45 (86.5)     146 (87.4)    0.787

  De Vita score (US activity), n (%)                                       0.006                                0.233

  Normal (0--1)                                16 (15.8)     16 (7.9)               12 (14.5)     20 (9.1)      

  Moderate (2--4)                              70 (69.3)     127 (62.9)             55 (66.3)     142 (64.5)    

  Severe (5--6)                                15 (14.9)     59 (29.2)              16 (19.3)     58 (26.4)     

  Positive RF, n (%)                           78 (77.2)     157 (78.1)    0.862    66 (79.5)     169 (77.2)    0.661

  Positive ANA, n(%)                           73 (72.3)     149 (73.8)    0.783    64 (77.1)     158 (71.8)    0.353

  Positive anti-SSA, n (%)                     82 (88.2)     187 (95.9)    0.014    73 (94.8)     196 (92.9)    0.562

  Positive anti-SSB, n (%)                     45 (44.6)     107 (53.0)    0.167    44 (53.0)     108 (49.1)    0.543

  Corticosteroids, n (%)                       43 (42.6)     118 (58.7)    0.008    39 (47.6)     122 (55.5)    0.221

  Hydroxychloroquine, n (%)                    77 (74.3)     149 (74.1)    0.981    64 (78.0)     160 (72.7)    0.347

  Azatioprine, n (%)                           0 (0)         16 (8.0)      0.003    5 (6.1)       11 (5.0)      0.771

  Methotrexate, n (%)                          2 (2.0)       16 (8.0)      0.038    2 (2.4)       16 (7.3)      0.115

  Cyclophosphamide, n (%)                      0 (0)         3 (1.5)       0.217    0 (0)         3 (1.4)       0.565f

  Lymphoma, n (%)                              0 (0)         8 (4.0)       0.043    3 (3.6)       5 (2.3)       0.516
  ----------------------------------------------------------------------------------------------------------------------

Low activity: ESSDAI\<5; Moderate to high activity: 5≥ESSDAI or Low activity: ESSPRI\<5; Moderate activity≥5. Except where indicated otherwise, values are the number (%); ESSDAI, EULAR Sjogren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjogren's Syndrome Patient Reported Index; EULAR European League Against Rheumatism; MSG minor salivary gland; RF rheumatoid factor; ANA antinuclear antibody; Anti-SSA Ab, anti-SSA antibody; Anti-SSB Ab, anti-SSB antibody;

Characteristics of pSS patients and SSDDI and SSDAI disease activity {#sec015}
--------------------------------------------------------------------

[Table 3](#pone.0226498.t003){ref-type="table"}. presents the characteristics of pSS patients with different grades of the SSDDI and SSDAI. Patients with moderate and high SSDDI scores showed higher US activity (p = 0.031) and more common lymphoma (p\<0.001) compared to SS patients with low disease activity. Patients with moderate SSDAI scores more frequently had positive biopsies of MSG (p = 0.015), positive anti-SSB (p = 0.033), concurrent therapy of corticosteroids (p = 0.019) and higher US activity (p = 0.01) compared to those of pSS patients with low disease activity.

10.1371/journal.pone.0226498.t003

###### Characteristics of pSS patients and comparison according to the level of its activity using SSDDI and SSDAI scores.
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  Characteristic                               SSDDI         p value      SSDAI     p value                     
  -------------------------------------------- ------------- ------------ --------- ------------- ------------- --------
  Age, mean±SD                                 54.13±12.17   54.73±9.24   0.808     54.71±11.99   53.71±11.90   0.467
  Female, n (%)                                270 (97.1)    24 (92.3)    0.207f    140 (97.9)    154 (95.7)    0.272
  Duration of disease, med (min-max)           5 (0--22)     7 (1--17)    0.059     5 (1--20)     5 (0--22)     0.404
  Xerophthalmia, n (%)                         253 (91.0)    24 (92.3)    0.824     129 (90.2)    148 (91.9)    0.600
  Xerostomia, n (%)                            255 (91.9)    25 (96.2)    0.451     131 (92.2)    149 (92.5)    0.923
  Positive keratoconjunctivitis sicca, n (%)   182 (96.3)    16 (94.1)    0.504f    90 (96.8)     108 (95.6)    0.658
  Positive sialo-scintigraphy, n (%)           139 (98.6)    11 (100.0)   1.000f    68 (98.6)     82 (98.8)     1.000f
  Positive biopsy of MSG, n (%)                173 (88.7)    18 (78.3)    0.150     80 (81.6)     111 (92.5)    0.015
  De Vita score (US activity), n (%)                                      0.031                                 0.001
  Normal (0--1)                                32 (11.6)     0 (0.0)                18 (12.7)     14 (8.7)      
  Moderate (2--4)                              182 (65.7)    15 (57.7)              103 (72.5)    94 (58.4)     
  Severe (5--6)                                63 (22.7)     11 (42.3)              21 (14.8)     53 (32.9)     
  Positive RF, n (%)                           215 (77.9)    20 (76.9)    0.909     106 (75.2)    129 (80.1)    0.302
  Positive ANA, n(%)                           231 (83.4)    24 (92.3)    0.234     116 (81.7)    139 (86.3)    0.269
  Positive anti-SSA, n (%)                     244 (93.1)    25 (96.2)    0.554     121 (91.0)    148 (95.5)    0.125
  Positive anti-SSB, n (%)                     140 (50.5)    12 (46.2)    0.669     62 (43.7)     90 (55.9)     0.033
  Corticosteroids, n (%)                       145 (52.5)    16 (61.5)    0.379     65 (46.1)     96 (59.6)     0.019
  Hydroxychloroquine, n (%)                    205 (74.3)    19 (73.1)    0.894     102 (72.3)    122 (75.8)    0.496
  Azatioprine, n (%)                           13 (4.7)      3 (11.5)     0.223f    4 (2.8)       12 (7.5)      0.120f
  Methotrexate, n (%)                          17 (6.2)      1 (3.8)      0.634     11 (7.8)      7 (4.3)       0.206
  Cyclophosphamide, n (%)                      2 (0.7)       1 (3.8)      0.237f    2 (1.4)       1 (0.6)       0.486
  Lymphoma, n (%)                              1 (0.4)       7 (26.9)     \<0.001   2 (1.4)       6 (3.7)       0.209

Except where indicated otherwise, values are the number (%); SSDAI, Sjogren's Syndrome Disease Activity Index; SSDDI, Sjogren's Syndrome Disease Damage Index; MSG minor salivary gland; RF rheumatoid factor; ANA antinuclear antibody; Anti-SSA Ab, anti-SSA antibody; Anti-SSB Ab, anti-SSB antibody; according to the chi-square test or Fisher\`s exact test where appropriate (f)

Predictive value of clinical, serological and sUS variables for moderate and high pSS activity and damage {#sec016}
---------------------------------------------------------------------------------------------------------

The results of logistic regression analyses ([Table 4](#pone.0226498.t004){ref-type="table"}) showed that severe US activity is an independent predictor of moderate and high pSS activity according to the ESSDAI score. The patients with a severe de Vita score (5--6) had a 3.5 times greater chance of having moderate or high disease activity. The presence of lymphoma increased extremely, with a 263.41-fold higher risk for moderate disease activity according to SSDAI. SSDAI greater than or equal to 5 highly correlated with positive biopsy of MSG (OR 3.061).

10.1371/journal.pone.0226498.t004

###### Odds ratios from multivariate logistic regression models for possible clinical, serological and sUS variables as predictors for moderate and high pSS activity assessed by clinical indexes.
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  -------------------------------------------------------------------------------------------------------------------------------
  Predictor                     ESSDAI\             ESSPRI\             SSDDI\     SSDAI\                                 
                                Moderate and high   Moderate and high   Moderate   Moderate                               
  ----------------------------- ------------------- ------------------- ---------- ---------- --------- --------- ------- -------
  De Vita score Normal (0--1)   ref                 ref                                       ref       ref       ref     ref

  De Vita score\                1.598               0.232                                     NA        0.998     0.588   0.350
  Moderate (2--4)                                                                                                         

  De Vita score\                3.556               0.007                                     NA        0.998     1.230   0.747
  Severe (5--6)                                                                                                           

  Age                                                                   1.013      0.299                                  

  Xerophthalmia                                                         2.075      0.113                                  

  Xerostomia                                                            2.147      0.116                                  

  Lymphoma                                                                                    263.428   \<0.001           

  Positive of biopsy of MSG                                                                                       3.061   0.020

  Positive anti-SSB                                                                                               1.585   0.133

  Glucocorticoids                                                                                                 1.533   0.153
  -------------------------------------------------------------------------------------------------------------------------------

ESSDAI, EULAR Sjogren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjogren's Syndrome Patient Reported Index; EULAR European League Against Rheumatism; SSDAI, Sjogren's Syndrome Disease Activity Index (SSDAI); SSDDI, Sjogren's Syndrome Disease Damage Index; MSG minor salivary gland; Anti-SSB Ab, anti-SSB antibody;

The diagnostic accuracy of a de Vita score ≥ 5 in comparison with ESSDAI, ESSPRI, SSDDI and SSDAI ≥ 5 is presented in [Table 5](#pone.0226498.t005){ref-type="table"}. The specificity of a severe de Vita sUS score for ESSDAI and SSDAI was 85.1% and 85.2%, respectively. In contrast, the sensitivity of a severe de Vita sUS score for ESSDAI was low, 29.2%, while the sensitivity for SSDAI was higher, 42.3%. In the analysis of disease activity, a de Vita score ≥ 5 could be a risk factor for moderate and high ESSDAI (p = 0.042) and SSDAI (p = 0.006). However, this could not be applied for ESSPRI and SSDDI (p\>0.05).

10.1371/journal.pone.0226498.t005

###### Diagnostic accuracy of a de Vita score ≥5 in comparison with ESSDAI, ESSPRI, SSDDI and SSDAI≥5.
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  -------------------------------------------------------------------------------------------------------------------
  De Vita score vs.           ESSDAI                ESSPRI                SSDDI                 SSDAI
  --------------------------- --------------------- --------------------- --------------------- ---------------------
  Sensitivity                 29.2%\                26.4%\                42.3%\                32.9%\
                              (95% CI 23.0--36.0)   (95% CI 20.7--32.7)   (95% CI 23.4--63.1)   (95% CI 25.7--40.8)

  Specificity                 85.1%\                80.7%\                77.3%\                85.2%\
                              (95% CI 76.7--91.4)   (95% CI 70.6--88.6)   (95% CI 71.9--82.1)   (95% CI 78.3--90.6)

  Overall accuracy            47.9%\                41.3%\                74.3%\                57.4%\
                              (95% CI 42.1--53.6)   (95% CI 35.7--47.0)   (95% CI 68.9--79.1)   (95% CI 51.6--63.1)

  Positive predictive value   79.7%\                78.4%\                14.9%\                71.6%\
                              (95% CI 68.8--88.2)   (95% CI 67.3--87.1)   (95% CI 7.7--25.0)    (95% CI 59.9--81.5)

  Negative predictive value   37.6%\                29.3%\                93.4%\                52.8%\
                              (95% CI 31.3--44.2)   (95% CI 23.5--35.6)   (95% CI 89.4--96.3)   (95% CI 46.2--59.4)

  Likelihood ratio +          1.97\                 1.37\                 1.86\                 2.23\
                              (95% CI 1.18--3.29)   (95% CI 0.84--2.24)   (95% CI 1.13--3.06)   (95% CI 1.42--3.50)

  Likelihood ratio -          0.83\                 0.91\                 0.75\                 0.79\
                              (95% CI 0.73--0.94)   (95% CI 0.80--1.04)   (95% CI 0.53--1.04)   (95% CI 0.69--0.89)

  Area under the ROC          57.2%                 53.5                  59.8                  59.1

  P                           0.042                 0.341                 0.099                 0.006
  -------------------------------------------------------------------------------------------------------------------

ESSDAI, EULAR Sjogren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjogren's Syndrome Patient Reported Index; EULAR European League Against Rheumatism; SSDAI, Sjogren's Syndrome Disease Activity Index (SSDAI); SSDDI, Sjogren's Syndrome Disease Damage Index.

Discussion {#sec017}
==========

In the clinical setting, the assessment of disease activity indexes is essential in patients with pSS. The relationship between different sUS scores and disease severity has been recently demonstrated \[[@pone.0226498.ref021]--[@pone.0226498.ref023]\]. However, these studies have focused only on EULAR indexes or associations between some of the clinical aspects of pSS with sUS damage. In our study, we tested the correlation of sUS using sets of indexes for disease activity developed by both Vitali et al. and the EULAR group. We found that a higher sUS score was associated with higher ESSDAI and SSDAI indexes of disease activity, with an estimated US diagnostic specificity for ESSDAI and SSDAI of 85.1% and 85.2%, respectively. To our knowledge, this was not previously reported.

The predictive value of different factors for disease activity, including parenchymal inhomogeneity as the sUS hallmark for pSS, has been demonstrated \[[@pone.0226498.ref024],[@pone.0226498.ref025]\]. Inhomogeneity of the salivary parenchyma detected by sUS includes the presence of hypoechoic areas and/or hyperechoic bands \[[@pone.0226498.ref026]\]. These sUS changes indicate active glandular inflammation due to the infiltration of immune cells and/or chronic damage with fibrotic lesions and loss of functional parenchyma \[[@pone.0226498.ref027]\]. Several sUS scoring systems have been proposed for the evaluation of typical sUS changes in pSS; however, no consensus has been reached yet \[[@pone.0226498.ref025]\]. In our study, grade 2 of the de Vita scoring system was denoted as abnormal sUS findings, and this cut-off value had the best diagnostic sensitivity (89.6%) and specificity (86.7%) for pSS, according to ROC curve analyses. Likewise, Jouse-Joulin et al. \[[@pone.0226498.ref028]\] reported that the diagnostic sensitivity of sUS for pSS ranged from 45.8% to 91.6% and that the specificity ranged from 73% to 98.1%.

Interestingly, in our cohort, 15 out of 202 (7.5%) pSS patients with ESSDAI ≥5 had normal sUS. The preserved US structure of the salivary glands with functional impairment in these cases indicates that other mechanisms may be involved in the pathogenesis of pSS, including abnormalities in parasympathetic neurotransmission \[[@pone.0226498.ref029]\]. In our cohort, 43% of the pSS patients had a duration of disease \<5 years, while 89.7% of these patients had pathological sUS. We found no correlation between disease duration and sUS change, similar to Theander E et al. \[[@pone.0226498.ref016]\]. This finding implies that changes in the salivary gland parenchymal echostructure are likely to be present in the early course of disease. On the other hand, we found positive correlations between sUS findings and indexes of disease activity and damage as well as serological tests, lymphoma and immunosuppressive therapy. Consistent with our findings, Fidelix et al. \[[@pone.0226498.ref015]\] reported an association of more severe sUS scores with an ESSDAI ≥ 5 and serological tests. Additionally, Kimura-Hayama E et al. \[[@pone.0226498.ref030]\] have also reported that elastography ultrasound of the major salivary glands correlates with the ESSDAI. However, this study did not find a correlation with the ESSPRI, similar to our results.

In our study group, 66.3% of pSS patients exhibited disease activity with an ESSDAI score ≥5, while only 3.1% of pSS patients had no systemic disease activity (ESSDAI = 0). According to Brito-Zeron et al. \[[@pone.0226498.ref031]\], pSS patients with high systemic disease activity are at high risk of death, and close follow-up (3--6 months) is strongly advised. In our study, analyses of domains of the ESSDAI revealed articular involvement as the most frequent finding (85%), followed by haematological (67.2%) and glandular (44%) involvement. This is in line with previously reported studies \[[@pone.0226498.ref032], [@pone.0226498.ref033]\]. Here, we found that pathological sUS correlated with the glandular domain within the ESSDAI and SSDDI. This is one possible reason for the higher disease activity, so sUS might be a surrogate item for the glandular domain in an objective measure of disease-related damage to salivary glands. Interestingly, disease longevity \> 5 years, de Vita scores ≥2, and current therapy with glucocorticoids and methotrexate were identified as variables independently associated with a higher ESSDAI score. In addition, we noted that abnormal sUS was an independent prognostic factor, whereas a severe de Vita score had high predictive value for high and moderate levels of ESSDAI and SSDAI.

However, some limitations of our study are worth noting. A progression of sUS changes in pSS patients could not be observed due to the cross-sectional design of this study. The main limitation of our research is related to the assessment of sUS score by a single ultrasonographer. Although the experienced ultrasonographer was blinded to the diagnosis, it is well known that sUS is a subjective method of imaging.

In conclusion, pathological salivary gland ultrasonography is associated with high disease activity and damage in pSS. Consequently, sUS abnormalities might represent a surrogate item for the glandular domain in the assessment of disease activity and damage. Thus, ultrasonography of the salivary glands combined with clinical and serological markers might be part of the next prognostic and therapeutic algorithm in the near future.
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###### The frequencies of domains in different ESSDAI scores.

Low activity: ESSDAI\<5; Moderate activity: 5≤ESSDAI≤13: High activity: ESSDAI≥14.
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###### The frequencies of domains in different ESSPRI scores.

Absence activity: ESSPRI 0; Low activity ESSPRI 5; Moderate and high activity: ESSPRI high ≥5.
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pSS

:   primary Sjogren's syndrome

sUS

:   salivary ultrasonography

EULAR

:   European League Against Rheumatism

ESSDAI

:   EULAR Sjogren's Syndrome Disease Activity Index

ESSPRI

:   EULAR Sjogren's Syndrome Patient Reported Index

SSDAI

:   Sjogren's Syndrome Disease Activity Index (SSDAI)

SSDDI

:   Sjogren's Syndrome Disease Damage Index

MSG

:   minor salivary gland

RF

:   rheumatoid factor

ANA

:   antinuclear antibody

Ab

:   antibody

Anti-SSA Ab

:   anti-SSA antibody

Anti-SSB Ab

:   anti-SSB antibody
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